Sugi Predict

Sugi Predict / Compounds / SCHEMBL408221

SCHEMBL408221

SCHEMBL408221

Cc1cn2c(n1)CCCC2

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.56
▸ ALDH1A1 P00352 3/20 0.56
▸ WDR5 P61964 8/20 0.44
▸ PDPK1 O15530 1/20 0.44
▸ NPC1 O15118 6/20 0.42
▸ RAB9A P51151 6/20 0.42
▸ HTT P42858 3/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ GAA P10253 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ TP53 P04637 2/20 0.41
▸ HPGD P15428 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ TSHR P16473 1/20 0.40
▸ POLB P06746 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.38
▸ MAPT P10636 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25768436 0.98 LMNA (0.54) LMNAALDH1A1WDR5PDPK1NPC1
SCHEMBL24879991 0.98 LMNA (0.54) LMNAALDH1A1WDR5PDPK1NPC1
SCHEMBL25772015 0.98 LMNA (0.54) LMNAALDH1A1WDR5PDPK1NPC1
SCHEMBL24869886 0.98 LMNA (0.54) LMNAALDH1A1WDR5PDPK1NPC1
SCHEMBL7916624 0.94 — —
SCHEMBL11187453 0.79 ALDH1A1 (0.51) LMNAALDH1A1WDR5PDPK1NPC1
SCHEMBL2716549 0.77 LMNA (0.49) LMNAALDH1A1WDR5PDPK1NPC1
SCHEMBL10064767 0.76 LMNA (0.53) LMNAALDH1A1WDR5PDPK1NPC1
SCHEMBL24880383 0.75 ALDH1A1 (0.47) LMNAALDH1A1WDR5PDPK1NPC1
SCHEMBL18850945 0.75 LMNA (0.47) LMNAALDH1A1WDR5PDPK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024089170-A1 ANTIBACTERIAL COMPOUNDS Janssen Sciences Ireland Unlimited Company (IE) 2024-05-02 — — WO disclosed
WO-2024080793-A1 NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME HANMI PHARM. CO., LTD. (KR) 2024-04-18 — — WO disclosed
WO-2024080792-A1 NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME HANMI PHARM. CO., LTD. (KR) 2024-04-18 — — WO disclosed
WO-2024028411-A1 COMBINATION THERAPY OF CDK7 INHIBITORS WITH OTHER ANTI-CANCER THERAPIES QURIENT CO., LTD. (KR) 2024-02-08 — — WO disclosed
WO-2023175173-A1 CDK7 INHIBITORS FOR ANTIVIRAL TREATMENT QURIENT CO., LTD. (KR) 2023-09-21 — — WO disclosed
WO-2023141323-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. (US) 2023-07-27 — — WO disclosed
US-20230210854-A1 MONO- AND COMBINATION THERAPIES RECURIUM IP HOLDINGS, LLC 2023-07-06 — — US disclosed
US-20230210854-A1 MONO- AND COMBINATION THERAPIES RECURIUM IP HOLDINGS, LLC 2023-07-06 — — US disclosed
WO-2023073090-A1 IMIDAZOPYRIDINE AMIDES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS Janssen Sciences Ireland Unlimited Company (IE) 2023-05-04 — — WO disclosed
WO-2023280254-A1 TEAD INHIBITOR 武汉人福创新药物研发中心有限公司 2023-01-12 — — WO disclosed
US-20120142714-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-06-07 — — US disclosed
WO-2012052451-A1 METABOTROPIC GLUTAMATE RECEPTOR MODULATORS MERZ PHARMA GMBH & CO. KGAA (DE) 2012-04-26 — — WO disclosed
US-20120065196-A1 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-15 — — US disclosed
WO-2012018909-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-09 — — WO disclosed
EP-2402329-A1 Analgetic phenylsulphonamides Boehringer Ingelheim International GmbH (DE) 2012-01-04 — — EP disclosed
US-20110294775-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-01 — — US disclosed
US-20110021488-A1 New Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-01-27 — — US disclosed
US-7589204-B2 Indane compounds as CCR5 antagonists SMITHKLINE BEECHAM CORPORATION (US) 2009-09-15 — — US disclosed
US-20090187021-A1 INDANE COMPOUNDS AS CCR5 ANTAGONISTS YOUNGMAN MICHAEL 2009-07-23 — — US disclosed
US-7271172-B2 Pyrrolidine and azetidine compounds as CCR5 antagonists SMITHKLINE BEECHAM CORPORATION (US) 2007-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021488-A1 New Compounds ABCG2, ADORA2B, ADORA3 LMNA 3828/4885ALDH1A1 428/4885WDR5 4463/4885
US-20110294775-A1 NOVEL COMPOUNDS TRPV1, OPRL1, TRPA1 LMNA 4630/4885ALDH1A1 2740/4885WDR5 2179/4885
US-20230210854-A1 MONO- AND COMBINATION THERAPIES TP53, BRCA1, MCL1 LMNA 3497/4885ALDH1A1 506/4885WDR5 2864/4885
US-20120142714-A1 BICYCLIC COMPOUND ACACA, ACACB, FABP4 LMNA 3226/4885ALDH1A1 172/4885WDR5 394/4885
US-20120065196-A1 AMIDE COMPOUNDS DGAT2, DGAT1, DLAT LMNA 4016/4885ALDH1A1 272/4885WDR5 3363/4885
US-20090187021-A1 INDANE COMPOUNDS AS CCR5 ANTAGONISTS CCR5, CCL5, IDO1 LMNA 4180/4885ALDH1A1 2472/4885WDR5 3251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.